These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 29616561)

  • 1. Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients.
    Morizio P; Burkhart JI; Ozawa S
    Ann Pharmacother; 2018 Oct; 52(10):1031-1041. PubMed ID: 29616561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.
    Sahota O; Narayanasamy M; Bastounis A; Paskins Z; Bishop S; Langley T; Gittoes N; Davis S; Baily A; Holmes M; Leonardi-Bee J
    Health Technol Assess; 2024 Apr; 28(21):1-169. PubMed ID: 38634483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
    Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
    Hiligsmann M; Reginster JY
    Pharmacoeconomics; 2011 Oct; 29(10):895-911. PubMed ID: 21692551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
    Palacios S; Agodoa I; Bonnick S; Van den Bergh JP; Ferreira I; Ho PR; Brown JP
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E487-92. PubMed ID: 25514106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
    Mori T; Crandall CJ; Ganz DA
    Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE; Yu J; Campbell HE; Abarca J; White TJ
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
    Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
    Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
    Freemantle N; Satram-Hoang S; Tang ET; Kaur P; Macarios D; Siddhanti S; Borenstein J; Kendler DL;
    Osteoporos Int; 2012 Jan; 23(1):317-26. PubMed ID: 21927922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.
    Kendler DL; McClung MR; Freemantle N; Lillestol M; Moffett AH; Borenstein J; Satram-Hoang S; Yang YC; Kaur P; Macarios D; Siddhanti S;
    Osteoporos Int; 2011 Jun; 22(6):1725-35. PubMed ID: 20827547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.
    Hadji P; Kyvernitakis I; Kann PH; Niedhart C; Hofbauer LC; Schwarz H; Kurth AA; Thomasius F; Schulte M; Intorcia M; Psachoulia E; Schmid T
    Osteoporos Int; 2016 Oct; 27(10):2967-78. PubMed ID: 27172934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
    Yoshizawa T; Nishino T; Okubo I; Yamazaki M
    Arch Osteoporos; 2018 Aug; 13(1):94. PubMed ID: 30159632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.
    Fleurence RL; Iglesias CP; Johnson JM
    Pharmacoeconomics; 2007; 25(11):913-33. PubMed ID: 17960951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M; Reginster JY
    Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.
    Park JH; Park EK; Koo DW; Lee S; Lee SH; Kim GT; Lee SG
    BMC Musculoskelet Disord; 2017 Apr; 18(1):152. PubMed ID: 28399834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.